Seres Therapeutics, Inc.
MCRB
Health Care
2
exclusion reasons
1 theme
This page is part of our public exclusion list — a transparency tool that shows which companies we screen out and why. It is not investment advice, and it is not an accusation. But it is subject to change as our understanding of the facts evolves.
Seres Therapeutics is a clinical-stage biotechnology company whose core research and development pipeline relies on animal testing. The company's lead investigational candidates, including SER-287 for ulcerative colitis and SER-109 for recurrent C. difficile infection, were advanced into human clinical trials based on evidence generated from preclinical studies conducted in multiple animal models of colitis. This use of animals in biomedical research is a standard, integral component of the company's drug development process.
Seres Therapeutics is a clinical-stage biotechnology company developing microbiome therapeutics for human diseases. Its product development pipeline requires extensive preclinical animal testing as part of the regulatory pathway for its investigational drugs. The company's SEC filings routinely cite the completion of animal studies as a standard part of its research process, referencing work in "multiple animal models of colitis" and other preclinical tests. This reliance on animal models is inherent to the pharmaceutical development process for novel biologic drugs like Seres's lead candidates.
Research Sources
1 organization
Related Exclusions
Wondering what we do invest in?
The Naughty List
A digest of changes to our exclusion list — new additions, removals, and the evidence behind them. We review the list continuously as new evidence surfaces.
Companies appear on our exclusion list based on our investment judgment — not because they've done anything illegal. This is a difference of values and opinion, not an accusation of wrongdoing. Exclusion does not constitute a recommendation against investing in any company, and absence from the list does not constitute a recommendation to invest.
This information is provided for educational and transparency purposes only and should not be relied upon as investment advice. Data is drawn from independent watchdogs, NGOs, government registries, and Ethical Capital's ongoing research — see Research Sources for the full list.
Ethical Capital LLC is a state-registered investment adviser in Utah (CRD #316032). Registration does not imply a certain level of skill or training.